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A 4-week-old Caucasian girl presented to her
local accident and emergency department with
a one-day history of difficulty breathing. She
had been born at 37 weeks gestation by spon-
taneous vaginal delivery. The pregnancy had
been complicated by mild intrauterine growth
restriction (weight on the 2nd centile) and
maternal genital chlamydia infection at
18 weeks gestation, which had been treated
with erythromycin. The delivery was unevent-
ful but she developed respiratory distress at
24 h of age and was admitted to the neonatal
unit. The results of investigations undertaken
during the early neonatal period are shown in
table 1. She was treated with intravenous
penicillin and gentamicin for presumed pneu-
monia, although no organism was isolated. She
improved and was discharged from hospital
aged 2 weeks. On examination in the A&E the
following were noted:
c Temperature 37.5uC
c Pallor
c Respiratory distress
c Oxygen saturation of 88% in air
c Right basal crepitations
c No dysmorphic features
c Weight and head circumference on the 2nd
centile.
The chest x ray is shown in figure 1 and the
results of blood tests in table 2.
The admitting registrar thought the chest x ray
showed right middle and lower lobe pneumonia. In
view of the history of maternal genital chlamydia
infection, chlamydia pneumonia formed part of the
differential diagnosis. Chlamydia IgG and IgM, as
well as eye swabs for Chlamydia PCR were
therefore sent. As the diagnosis of Chlamydia
pneumonia was less likely than typical pneumonia
given the full course of treatment her mother had
received during pregnancy, she was started on
intravenous cefotaxime and gentamicin.
Supplementary oxygen was given via a nasal
cannula.
COMMENT
c Neonatal chlamydia infection is contracted
during parturition. Up to 70% of infants born
to mothers with genital chlamydia infection
are infected.1
c Conjunctival mucosa is the most commonly
infected area, causing ophthalmia neonatorum.
This usually presents at 5–14 days of age with
conjunctivitis and often erythema and oedema
of the eyelid. There is often a watery discharge,
which may later become purulent. Untreated,
most infections resolve spontaneously within
the first few months of life, but corneal
scarring has been reported.2
c Chlamydia pneumonia develops in 7% of
infants born to infected mothers.3 It typically
occurs at 6 weeks of age but occasionally as
early as the first week of life. A low grade fever,
staccato cough and tachypnoea are typical.
Treatment is with oral or systemic erythromy-
cin for 14 days. Detection and treatment are
important because longitudinal studies have
shown an increased incidence of chronic cough
and impaired lung function when compared
with age-matched controls.4
c Diagnosis is made by either culture or PCR of
respiratory secretions, and by the detection of
chlamydia IgM, which may be positive within
5 days.5 Chlamydia is an intracellular patho-
gen, so it is most readily isolated from speci-
mens containing epithelial cells, such as those
from the conjunctiva.
c Rapid diagnosis by PCR is also possible from
eye swabs. This is becoming the investigation
of choice because the sensitivity and specificity
are good.6
Although mild neutropenia had been noted during
the early neonatal period, the current profound
Figure 1 Chest x ray at initial presentation.
Table 1 Blood results on day 2 of life.
Investigation Result
Haemoglobin 14.9 g/dl
White cell count 4.016109/l
Neutrophil count 0.826109/l
Lymphocyte count 3.036109/l
Platelet count 1566109/l
C-reactive protein 4 mg/l
Blood film Mild neutropenia, but normal morphology.
Likely to be secondary to intercurrent
infection
Problem solving in clinical practice
14 Arch Dis Child Educ Pract Ed 2008;93:14–18. doi:10.1136/adc.2006.109264
 group.bmj.com on June 8, 2010 - Published by ep.bmj.comDownloaded from 
neutropenia was unexpected. As the possibility of
an immunodeficiency existed a combined consul-
tation with the immunology and infectious disease
team and the haematologist was sought. The most
likely explanation was thought to be either allo-
immune or autoimmune neutropenia, both of
which would resolve spontaneously. Also, neutro-
penia secondary to a congenital or acquired
infection (for example, cytomegalovirus or chla-
mydia) or severe congenital neutropenia were
considered. The potential causes of congenital
neutropenia are numerous and listed in table 3.
Regardless of the specific cause, it was decided to
give daily injections of Granulocyte Colony
Stimulating Factor (G-CSF) to treat the neutrope-
nia and liposomal amphotericin to minimise the
risk of an invasive fungal infection.
She was commenced on clarithromycin to
treat a possible chlamydia infection, in addi-
tion to the liposomal amphotericin and G-CSF.
She was noted to have a normochromic
normocytic anaemia (table 2) and in view of
this and the continued need for supplemen-
tary oxygen, a blood transfusion was given.
The results of further investigations are
shown in table 4.
COMMENT
c Neutrophils are the predominant leucocyte in
the peripheral blood, although a reversed
differential with lymphocytes exists from
48 h of age until approximately 6 months.
Neutrophils are an integral effector cell of
innate immunity and as such, have a critical
role in detecting and rapidly responding to
invading micro-organisms, as well as initiating
wound repair and healing.
c Bone marrow production of neutrophils occurs
in two stages; first the mitotic stage (myelo-
blasts, promyelocytes and myelocytes) and
second the maturation phase (metamyelocytes,
bands and polymorphs). Falling numbers of
peripheral neutrophils are detected by tissue
macrophages that produce IL-23 which ulti-
mately acts on stromal cells to release G-CSF
that stimulates haematopoietic stem cells to
follow a maturation route that will end in the
release of polymorphs into the circulation.7
c Once activated, neutrophils become ‘‘sticky’’.
They then adhere to vascular epithelium and
matrix, and move into adjacent tissue. Once in
contact with an invading pathogen, the neu-
trophil discharges highly reactive oxidant inter-
mediates leading to tissue and pathogen
destruction and pus formation.
c Neutropenia is classified as mild (.1.06109/l),
moderate (0.5–1.06109/l), severe (0.2–0.56109/l)
and very severe (,0.26109/l).12 The risk of severe
infection does not increase until the neutrophil
count falls below 0.56109/l and varies according
to the underlying cause and the duration of the
neutropenia. The host is typically susceptible to
gram-negative, streptococcal and fungal infec-
tion. Infections need to be aggressively treated
with broad spectrum antibiotics and if necessary
anti-fungals. The decision to use prophylactic
antibiotics in neutropenia is based on both the
clinical picture and the severity of the neutrope-
nia. Co-trimoxazole is the prophylactic antibio-
tic of choice.8
The girl gradually improved during the next
4 days. Eight days after hospital admission the
neutrophil count was 2.516109/l (within nor-
mal limits) and 10 days after admission (8 days
after starting G-CSF) it was 12.116109/l.
COMMENT
c Granulocyte colony stimulating factor (G-CSF)
is a naturally occurring cytokine produced by
macrophages, endothelium and other immune
cells that acts directly on haemopoetic stem
cells and thus increases the numbers of
circulating neutrophils.
c It is coded for on chromosome 17 and
recombinant human G-CSF is synthesised in
an E coli expression system.
c G-CSF has been used for many years to treat
children recovering from chemotherapy and a
recent Cochrane review stated that there
appeared to be a reduction in mortality in
neonates with sepsis and associated neutrope-
nia treated with G-CSF, although further
research was needed.9
c Long-term G-CSF use may sporadically be
associated with other complications such as
osteopenia, potentially via osteoclast activa-
tion,10 and glomerulonephritis.11
She was now symptom-free and started to grow
along the 0.4th centile. The G-CSF was therefore
discontinued, but within 48 h the neutrophil
count had dropped to 0.696109/l (fig 2) although
her haemoglobin concentration remained satis-
factory. She was therefore transferred to the
specialist haematology unit to investigate the
possibility of primary bone marrow disease. A
bone marrow aspirate and trephine (fig 3)
revealed a moderately cellular specimen with
all cell lines represented. Granulopoeisis was
Table 2 Blood results at second presentation
Investigation Result
Haemoglobin 8.0 g/dl
MCH 30.9 pg
MCV 88.3 fl
Reticulocyte count 376109/l
White cell count 2.066109/l
Neutrophils 0.056109/l
Lymphocytes 2.16109/l
Platelet count 1986109/l
C-reactive protein 19 mg/l
Renal function Normal
Blood film Anaemia and profound neutropenia with reactive
lymphocytes. No notable neutrophil morphology.
No primitive cells seen. Normal red cell
morphology, no fragments seen
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slightly reduced but certainly present with
maturation through to the neutrophil stage.
The most likely problem was thought to be with
neutrophil destruction, either benign alloimmune
or autoimmune neutropenia, but the results of
neutrophil antibody tests, which could confirm
these diagnoses, were outstanding. A primary bone
marrow problem was considered unlikely and
neutrophil maturation arrest (Kostmann syn-
drome) had been excluded.
She was discharged from hospital and her
neutrophil count was regularly measured as
an out-patient.
COMMENT
c Neonatal alloimmune neutropenia has an
incidence of less than 0.1% and occurs when
maternal antibodies, produced in response to
paternally inherited fetal neutrophil antigens,
bind to and destroy fetal neutrophils.12 The
mechanism is similar to Rhesus haemolytic
disease of the newborn, but unlike Rhesus
disease, neonatal alloimmune neutropenia
commonly occurs in the first pregnancy.13
The diagnosis is confirmed by demonstration
of maternal and baby neutrophil specific
antibodies against paternally inherited anti-
gens. The neutropenia may be severe but
despite this infections are rarely severe. No
specific therapy is indicated and the neutrope-
nia resolves between 3–28 weeks (average
11 weeks). There is a high risk of recurrence
for future pregnancies.
c Primary autoimmune neutropenia, a relatively
benign disorder, is characterised by neutrophil
specific auto-antibodies. There is often severe
neutropenia but as with allo-immune neutrope-
nia, severe infections are rare and specific
treatment with G-CSF and prophylactic anti-
biotics is not usually necessary. Diagnosis relies
on finding neutrophil specific antibodies. The
Figure 2 Changing neutrophil numbers with time.
Table 3 Causes of congenital neutropenia
Classification Condition Details
Immune mediated Neonatal allo-immune (NAIN) c Maternal neutrophil specific antibodies
c Infections rarely severe
c Average age of recovery is 11 weeks
Primary auto-immune
neutropenia
c No treatment is usually necessary
c Neutrophil specific auto-antibodies
c Severe neutropenia but few severe infections
c Spontaneous recovery in 95% (17 months)
c G-CSF may be necessary if infection severe
Genetic Severe congenital neutropenia
(Kostmann syndrome)
c Autosomal recessive, autosomal dominant or
sporadic
c Presents in infancy with severe neutropenia
and infection
c Bone marrow shows maturation arrest at the
promyelocyte/myelocyte stage.
c Treat with lifelong G-CSF and antibiotics
c Risk of malignant transformation (12%)
Cyclical neutropenia c Autosomal dominant
c 21 day cycle of neutropenia (3–5 days)
c Presents with recurrent fever, mouth ulcers and
respiratory symptoms
c No increased risk of malignancy
c Responds well to G-CSF
Rarer causes Shwachman-Diamond c Autosomal recessive
c Neutropenia, skeletal abnormalities and
exocrine pancreatic insufficiency
Glycogen storage disease 1b c Mechanism neutropenia unclear
c Treat with lifelong G-CSF
Wiskott-Aldrich (with WASp
activating mutatons)
c X-linked
c Combination eczema, neutropenia and
thrombocytopaenia
CD40 ligand deficiency c X-linked
c High IgM, low IgG and IgA, neutropenia
c Recurrent infections and autoimmune disease
Pearson’s syndrome c Caused by mitochondrial DNA deletions
c Refractory sideroblastic anaemia, neutropenia,
thrombocytopaenia and exocrine pancreatic
failure
Barth syndrome c X-linked
c Mutation in G4.5 gene which encodes for a
protein involved in cardiolypin biosynthesis
c Associated with cardiomyopathy
c Requires early treatment with G-CSF
Cartilage hair hypoplasia c Autosomal recessive
c Short stature, sparse hair, neutropenia and
anaemia
Idiopathic Idiopathic neutropenia c Diagnosis of exclusion
c Few infections and good response to G-CSF
c No risk of malignant transformation
Table 4 Recommended initial investigations
Investigation Result
Chlamydia PCR (nasal secretions) Negative
Chlamydia PCR (eye swabs) Negative
Chlamydia serology Negative
CMV IgM Not detected
CMV PCR (serum) Negative
CMV PCR (urine) Negative
EBV IgM Not detected
Parvovirus IgM Not detected
Parvovirus serology Negative
Toxoplasma IgG Not detected
Respiratory viruses panel Negative
NPA Negative
Lymphocyte subsets Normal
Antineutrophil antibodies Not detected
x ray left wrist Normal
Chromosome fragility for Fanconi’s anaemia Normal
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condition is self-resolving, often with complete
recovery by an average age of 17 months from
diagnosis.
FURTHER PROGRESS
At 3 months of age, she again developed the
clinical features of pneumonia. The neutrophil
count was 0.436109/l. The neutrophil antibody
test results were now available and excluded
alloimmune and autoimmune neutropenia.
The absence of neutrophil antibodies does not
wholly exclude the diagnosis of autoimmune
neutropenia because in approximately 30% of cases
no antibody is found. The combination of negative
antibodies together with two episodes of sepsis in
association with the neutropenia made the diag-
nosis in this case unlikely.
The pneumonia was successfully treated
with antimicrobials and G-CSF. However,
she was now failing to thrive (weight below
the 0.4th centile) and further questioning
revealed that since birth she had had frequent,
large and foul-smelling stools. Stool micro-
scopy showed numerous fat globules and
faecal elastase was markedly reduced (42 mg/
g). A sweat test excluded cystic fibrosis.
The results were diagnostic of fat malabsorption
secondary to severe exocrine pancreatic insuffi-
ciency. This, together with the congenital neutro-
penia, suggested a diagnosis of Shwachman-
Diamond syndrome.
COMMENT
c Shwachman-Diamond syndrome (SDS) is a
rare multisystem disorder characterised by
bone marrow dysfunction, exocrine pancreatic
insufficiency and bony abnormalities (classi-
cally metaphyseal chondrodysplasia). It is the
second most common cause of exocrine pan-
creatic insufficiency after cystic fibrosis and
affects 1 in 100 000–200 000 births.
c It is an autosomal recessive condition caused by
dysfunction of the Shwachman-Bodian-
Diamond syndrome (SBDS) gene located on
chromosome 7q11,14 of which 14 different
mutations have been identified. This gene
abnormality results in defective protein accu-
mulation in the nucleosome, cytoplasm and
sites of mRNA synthesis such as ribosomes.
c Diagnosis is based on clinical grounds aided by the
criteria used by Dror and Freedman.15 Bone
marrow aspiration is often performed to exclude
an infiltrative or primary bone marrow disease,
and shows variable marrow cellularity and
granulopoiesis with variable degrees of ‘‘left
shift’’. Molecular tests are now available for the
different mutations and can be invaluable to
remove diagnostic uncertainty in difficult cases.
There is however poor genotype/phenotype
correlation.
c Although all patients with SDS have exocrine
pancreatic involvement, diagnosed by two
stool elastases ,500 mg/g collected at a time
when the patient is without gastrointestinal
disturbance, there is a significant variation in
phenotype, with some patients becoming
pancreatic sufficient with increasing age.16
Unlike cystic fibrosis, the pancreatic ducts are
preserved but there is paucity of acini and fatty
replacement of the gland. Abdominal ultra-
sound and CT scan show a small abnormal
pancreas mainly composed of fat, and can aid
the diagnosis. Treatment is with pancreatic
enzyme replacement therapy.
c 95% of patients with SDS will have either chronic
or intermittent neutropenia. Anaemia, thrombo-
cytopaenia and pancytopaenia have also been
reported. Specific abnormalities of T and B cell
numbers and function are also recognised, includ-
ing low IgG or IgG subclasses, low percentage of
circulating B lymphocytes, decreased in vitro B-
lymphocyte proliferation and a lack of specific
antibody production. These deficiencies are often
overlooked and some patients may need antibody
replacement therapy.17
c The main adverse outcomes associated with
SDS are:
– bone marrow failure, in particular over-
whelming sepsis secondary to neutropenia
– transformation to myelodysplastic syndrome
(MDS) and acute myeloid leukaemia (AML).
c The neurophil count in SDS responds to G-CSF
administration. There is no doubt that G-CSF
availability and use has had a considerably
beneficial effect on the mortality from infec-
tion in this condition. Two large case series of
patients with congenital neutropenia syn-
dromes treated with G-CSF have demonstrated
a correlation between the incidence of the
development of MDS and AML and the
amount of G-CSF used.18 19 It is not clear
whether this is due to a leukaemogenic effect
of G-CSF, or to the fact that the more severely
neutropenic and less responsive cases were
more likely to transform anyway because of
the biology of their underlying disease. Rather
than using long-term prophylactic G-CSF
Figure 3 Bone marrow trephine showing proliferation of
pro-myelocytes through to the myelocyte stage, thus
excluding Kostmann syndrome.
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routinely in order to maintain a numerically
satisfactory neutrophil count, it seems prudent
to tailor G-CSF use individually. Prophylaxis
may be used in individuals demonstrating a
propensity to infection, and therapeutic use
together with antibiotic therapy employed for
febrile neutropenic episodes.
c The risk of malignant transformation is 24%,
but is increased to 70% in a subgroup of
patients with pre-existing pancytopaenia, mye-
lodysplastic features and clonal cytogenetic
abnormalities.20 Allogenic bone marrow trans-
plantation (BMT) is the only chance of cure in
these patients as conventional chemotherapy
fails to regenerate normal haemopoiesis in the
majority, but carries its own risks of complica-
tions and overwhelming sepsis. Evidence from
two case series suggests that BMT in SDS can
be well tolerated but the outcome is poor in
those who have already transformed to AML/
MDS.21 22 Ideally, the subgroup of patients
identified as at risk to progression should be
identified and transplanted pre-emptively.
c Infants are often on the lower height and weight
centiles, but the characteristic abnormality is
metaphyseal chondrodysplasia. Recent studies
have suggested that children with SDS may
suffer from learning and behavioural difficulties.15
Genetic tests have confirmed the diagnosis of
SDS. This patient is now on prophylactic
antibiotics and enzyme replacement therapy.
She is thriving with a weight on 0.4th centile
and length 4 cm below the 0.4th centile.
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